Pfizer Inc. $PFE Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,442,594 shares of the biopharmaceutical company’s stock after purchasing an additional 9,639 shares during the period. Handelsbanken Fonder AB’s holdings in Pfizer were worth $59,208,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter valued at approximately $27,000. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the 2nd quarter worth $29,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Trading Down 1.9%

Shares of Pfizer stock opened at $24.41 on Friday. The company has a fifty day simple moving average of $24.82 and a 200-day simple moving average of $24.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $138.79 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.